Brenig Therapeutics to Present AI-Enabled Design of a Brain-Penetrant NLRP3 Inhibitor at Keystone Symposia Neuroinflammation in Health and Disease

BOSTON and SAN DIEGO, June 22, 2026 /PRNewswire/ -- Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company developing differentiated therapies for neurodegenerative and neuroinflammatory diseases, today announced that Alexei Pushechnikov, PhD, will present new data on...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.